News
BarentsKrans advises Mourik on the acquisition of 50% of the shares in Van Spijker Infrabouw B.V.
BarentsKrans has advised Mourik on the acquisition of 50% of the shares in Van Spijker Infrabouw B.V. located in Meppel. Kees Jan Mourik, CEO of Mourik, states that “Van Spijker has the same predilection as Mourik for innovation to carry out projects much more smarter and cleaner. Mourik and Van Spijker have a mutual focus
Read more ›
Legal 500: splendid results for BarentsKrans
Legal 500 has published the 2021 rankings. The publication ranked BarentsKrans as a Top Tier Firm in Employment and Commercial Litigation. We also entered Tier 3 with Environment and Planning. Legal 500 is one of the most prominent guides on the international legal profession. Below you will find an overview of our rankings in the
Read more ›
Dutch Supreme Court confirms possibility to change the priority of rights of pledge (without releasing them)
On 9 April 2021, the Dutch Supreme Court has confirmed the possibility to change the priority of rights of pledge (pandrechten) in deviation of the prior tempore rule. A change to the priority of rights of mortgage (hypotheekrechten) (in relation to earlier vested rights of mortgage or rights in rem) is explicitly stated in the
Read more ›
Chambers Europe 2021 about BarentsKrans: ‘excellent service, impressive and helpful’
Last month we published the stunning results that BarentsKrans achieved in the Chambers 2021 Global edition. Meanwhile, the Chambers Europe guide has also been published and we would, once again, like to share our Chambers feedback with you. Chambers and Partners publishes her rankings annually and in doing so compares 52 jurisdictions across Europe, from
Read more ›
Chambers Global 2021 rankings: excellent results for BarentsKrans
Chambers Global 2021, the guide that provides a worldwide overview of international practice areas, has just been released. BarentsKrans received several honourable mentions. BarentsKrans has a number of wonderful mentions for Corporate/M&A, Intellectual Property and Dispute Resolution. Feedback from clients and peers The yearly Chambers ranking lists are based upon feedback received from clients as
Read more ›
New development in litigation against Heineken and its Greek subsidiary
In one of the most prominent abuse of dominance cases pending in the Netherlands, the Amsterdam Court of Appeal last week reversed a judgment of the Amsterdam District Court. In 2017 Macedonian Thrace Brewery (MTB) commenced proceedings against Heineken N.V. and its Greek subsidiary Athenian Brewery (AB) for abuse of dominance in the Greek beer
Read more ›
The first court rulings on the new Dutch Restructuring Act
Since 1 January 2021, a formal Dutch pre-insolvency arrangement is made available with the implementation of the Act on Court Confirmation of Extrajudicial Restructuring Plans (in Dutch: Wet Homologatie onderhands akkoord ter voorkoming van faillissement, “WHOA”), also known as the Dutch Scheme. It provides a restructuring tool to prevent insolvency of (partly) viable companies or
Read more ›
Telecoms update | District Court rejects infringement claim
On 30 December 2020 (published 13 January 2021), the District Court of The Hague (“the Court”) rendered a judgment in final relief proceedings initiated by Adaptive Spectrum and Signal Alignment, Incorporated (“ASSIA”) against Koninklijke KPN N.V., Telfort Zakelijk B.V., XS4ALL Internet B.V., KPN B.V. (collectively “KPN”) and Nokia Solutions and Networks Nederland B.V. (“Nokia”) regarding
Read more ›
BarentsKrans advises Horticoop on the acquisition of the shares in SmartCoat B.V.
BarentsKrans has advised Horticoop on the acquisition of the shares in SmartCoat B.V. from Finoxa. Horticoop already held 80% of the shares and became the sole shareholder of Smartcoat at the end of 2020 as a result of this transaction. SmartCoat is with her brands Redusysems and Sudlac active in more than 50 countries and
Read more ›
BarentsKrans advises Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics
BarentsKrans has advised Angelini Pharma on the acquisition of the shares in Arvelle Therapeutics. Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS (Central Nervous System) disorders. “At Angelini Pharma, we are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our
Read more ›
